

# ERG

Concentrated and Prediluted Monoclonal Antibody  
901-421-101520

**BIOCARE**  
M E D I C A L

Available Product Formats				
Format	Catalog Number	Description	Dilution	Diluent
Concentrate	CM 421 A, C	0.1, 1.0 mL	1:100	Renoir Red
Predilute	PM 421 AA	6.0 mL	Ready-to-use	N/A
ONCORE	OAI 421 T60	60 tests	Ready-to-use	N/A
ONCORE Pro	OPAI 421 T60	60 tests	Ready-to-use	N/A
UltraLine – For BenchMark	VP 421 G	6.0 mL	Ready-to-use	N/A

## Intended Use:

For In Vitro Diagnostic Use

ERG [9FY] is a mouse monoclonal antibody that is intended for laboratory use in the qualitative identification of ERG protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

## Summary and Explanation:

In human prostate cancer, the ERG oncogene is frequently overexpressed due to chromosomal translocations involving ERG and regulatory sequences of the TMPRSS2 or other androgen responsive genes.

In particular, the TMPRSS2:ERG fusion gene has recently been found to be the most frequent gene rearrangement in prostate cancers, occurring in 45-65% of North American patients.

The mouse monoclonal anti-ERG antibody, clone 9FY, shows an unprecedented 99.9% specificity for detecting prostatic adenocarcinoma. Independent reports demonstrate 97-100% correlation between the expression of the ERG protein and the presence of TMPRSS2:ERG rearrangement and a remarkable concordance (96.5%) of ERG positive prostatic intraepithelial neoplasia (PIN) and ERG positive carcinoma in prostatectomy specimens.

Therefore, as a hallmark of the TMPRSS2:ERG chromosomal translocation, detection of ERG expression by 9FY offers a rare, but definitive marker of adenocarcinoma of prostatic origin, and unique opportunities to indicate oncogenic activations in PIN, to stratify prostate cancer patients for ERG oncogene status and to monitor treatment efficacy. Towards the stratification of patients, comparative evaluations of ERG protein expression status with 9FY and TMPRSS2-ERG gene fusions in hormone-naïve and castration resistant prostate cancers have shown promise for defining a subgroup of cases with dispensed androgen signaling pathway.

Given the ease of performing IHC vs. FISH, ERG protein expression in formalin-fixed paraffin-embedded (FFPE) tissues may be an extremely useful tool for the routine identification of the ERG gene rearrangement and diagnosis of prostatic adenocarcinoma.

Further utility of the mouse monoclonal anti-ERG antibody, 9FY, has been shown in detecting endothelial malignancies, including Kaposi sarcoma. Reports have also demonstrated the superior performance of 9FY in chromatin immunoprecipitation (ChIP), immunofluorescence (IF) and immunoblot assays.

*Note: Clone 9FY [U.S. Patent 8,765,916 and patents pending] was developed by the Center for Prostate Disease Research with the Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, Maryland, USA.*

## Principle of Procedure:

Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. After labeling the antigen with a primary antibody, a one-, two- or three-step detection procedure can be employed. The one-step procedure will feature an enzyme-labeled polymer that binds to the primary antibody. A two-step procedure will feature a secondary antibody added to bind to the primary

## Principle of Procedure Cont'd:

antibody. An enzyme-labeled polymer is then added to bind to the secondary antibody. The three-step detection procedure will feature a secondary antibody added to bind to the primary antibody followed by a linker antibody step for maximum binding. An enzyme-labeled polymer is then added to bind to the linker antibody. These detections of the bound antibodies are evidenced by a colorimetric reaction.

**Source:** Mouse monoclonal

**Species Reactivity:** Human; others not tested

**Clone:** 9FY

**Isotype:** IgG1

**Protein Concentration:** Call for lot specific Ig concentration.

**Epitope/Antigen:** N-terminal ERG (see Technical Notes)

**Cellular Localization:** Nuclear

**Positive Tissue Control:** ERG positive prostate cancer and/or PIN glands

**Known Applications:**

Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

**Supplied As:** Buffer with protein carrier and preservative

**Storage and Stability:**

Store at 2°C to 8°C. The product is stable to the expiration date printed on the label, when stored under these conditions. Do not use after expiration date. Diluted reagents should be used promptly; any remaining reagent should be stored at 2°C to 8°C.

## Protocol Recommendations (intelliPATH FLX® and manual use):

**Peroxide Block:** Block for 5 minutes with Peroxidized 1.

**Pretreatment:** Perform heat retrieval using Reveal or Diva Decloaker. Refer to the Reveal or Diva Decloaker product data sheet for specific instructions.

**Protein Block (Optional):** Incubate for 5-10 minutes at RT with Background Punisher.

**Primary Antibody:** Incubate for 30-60 minutes at RT.

**Probe:** Incubate for 10 minutes at RT with a secondary probe.

**Polymer:** Incubate for 10-20 minutes at RT with a tertiary polymer.

**Chromogen:** Incubate for 5 minutes at RT with Biocare's DAB - OR - Incubate for 5-7 minutes at RT with Warp Red.

**Counterstain:**

Counterstain with hematoxylin. Rinse with deionized water. Apply Tacha's Bluing Solution for 1 minute. Rinse with deionized water.

**Technical Notes:**

1. ERG [9FY] is highly specific and does not stain lymphocytes.
2. ERG [9FY] has been shown to stain endothelial cells, which may serve as a convenient internal positive control in most tissue sections.
3. ERG [9FY] was raised against an N-terminal epitope. Thus, it recognizes most forms of ERG proteins, such as ERG8 encoded by the dominant ERG mRNAs in prostate cancer. In contrast, other antibodies raised exclusively against C-terminal epitopes of ERG do not recognize ERG8 and other cancer associated forms of ERG that lack C-terminal sequences.
4. This antibody, for intelliPATH FLX and manual use, has been standardized with MACH 4 detection system. Use TBS for washing steps.

## ERG

Concentrated and Prediluted Monoclonal Antibody  
901-421-101520

**BIOCARE**  
M E D I C A L

### **Protocol Recommendations (ONCORE™ Automated Slide Staining System):**

OAI421 is intended for use with the ONCORE. Refer to the User Manual for specific instructions for use. Protocol parameters in the Protocol Editor should be programmed as follows:

**Protocol Name:** ERG

**Protocol Template (Description):** Ms HRP Template 1

**Dewaxing (DS Option):** DS2

**Antigen Retrieval (AR Option):** AR1, high pH; 103°C

**Reagent Name, Time, Temp.:** ERG, 30 min., 25°C

### **Protocol Recommendations (ONCORE™ Pro Automated Slide Staining System):**

OPA1421 is intended for use with the ONCORE Pro. Refer to the User Manual for specific instructions for use. Protocol parameters in the Protocol Editor should be programmed as follows:

**Protocol Name:** ERG

**Protocol Template (Description):** Ms HRP Template 1

**Dewaxing (DS Buffer Option):** DS2-50

**Antigen Retrieval (AR Option):** AR1, high pH; 103°C

**Block Option:** Buffer

**Reagent Name, Time, Temp.:** ERG, 30 min., 25°C

### **Protocol Recommendations (Ventana BenchMark ULTRA Slide Staining Systems):**

VP421 is intended for use with the Ventana BenchMark ULTRA Slide Staining System. Refer to the User Manual for specific instructions for use. Recommended protocol parameters are as follows:

**Template / Detection:** ultraView DAB

**Pretreatment Protocol:** ULTRA CC1 Standard

**Primary Antibody:** 32 minutes, No Heat

**ultraBlock (V-Blocker BRI4001):** Incubate for 4 minutes (with appropriate Option # registered by user)

V-Blocker is recommended to be applied prior to any detection system.

- Protocol Recommendation for Ventana BenchMark XT available upon request.

### **Quality Control:**

Refer to CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2). CLSI Wayne, PA, USA (www.clsi.org). 2011

### **Precautions:**

1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN<sub>3</sub>) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (8)

2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents

### **Precautions Cont'd:**

or specimens come into contact with sensitive areas, wash with copious amounts of water. (9)

3. Microbial contamination of reagents may result in an increase in nonspecific staining.

4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.

5. Do not use reagent after the expiration date printed on the vial.

6. The SDS is available upon request and is located at <http://biocare.net>.

### **Limitations:**

The optimum antibody dilution and protocols for a specific application can vary. These include, but are not limited to fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, as results may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions.

### **Troubleshooting:**

Follow the antibody specific protocol recommendations according to data sheet provided. If atypical results occur, contact Biocare's Technical Support at 1-800-542-2002.

### **References:**

1. Petrovics G, *et al.* Frequent overexpression of *ETS* related gene-1 (*ERG1*) in prostate cancer transcriptome. *Oncogene*. 2005 May 26;24(23):3847-52.
2. Rosen P, *et al.* Clinical potential of the ERG oncoprotein in prostate cancer. *Nat Rev Urol*. 2012 Feb 14;9(3):131-7.
3. Furusato B, *et al.* ERG oncoprotein expression in prostate cancer: clonal progression of ERG positive tumor cells and potential for ERG based stratification. *Prostate Cancer Prostatic Dis*. 2010 Sep;13(3):228-37.
4. Braun M, *et al.* ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer - a comparative study of two monoclonal antibodies. *Prostate Cancer Prostatic Dis*. 2012 Jun;15(2):165-9.
5. Miettinen M, *et al.* ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. *Am J Surg Pathol*. 2011 Mar;35 (3):432-41.
6. Mohamed AA, *et al.* Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody. *J Cancer*. 2010 Oct 25;1:197-208.
7. Mohamed AA, *et al.* ERG oncogene modulates prostaglandin signaling in prostate cancer cells. *Cancer Biol Ther*. 2011 Feb 15;11(4):410-7.
8. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts."
9. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.

VP Echelon Series antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare's antibodies by Ventana Medical Systems, Inc. Biocare and Ventana are not affiliated, associated or related in any way. Ventana®, BenchMark®, ultraView and OptiView are trademarks of Roche.

# ERG


Concentrated and Prediluted Monoclonal Antibody  
901-421-101520

**BIOCARE**  
M E D I C A L

## Applications of anti-ERG [9FY]


Western Blot, Immunofluorescence (IF) & Chromatin Immunoprecipitation (ChIP)

### Western blot of 9FY



ERG-MAb, 9FY was raised against an N-terminal epitope. Thus, it recognizes most forms of ERG proteins, such as ERG8 encoded by the dominant ERG mRNAs in prostate cancer. In contrast, other antibodies raised exclusively against C-terminal epitopes of ERG do not recognize ERG8 and other cancer associated forms of ERG that lack C-terminal sequences.


### Immunofluorescence using 9FY



Nuclear localization of endogenous ERG oncoprotein is shown by anti-ERG [9FY] in VCaP prostate cancer cells (ERG). Inhibition of ERG expression in response to ERG knockdown (ERG siRNA) demonstrates the specificity of anti-ERG [9FY]. In corresponding images above, nuclear staining of VCaP cells are visualized by DAPI.

[www.biocare.net](http://www.biocare.net)

### Chromatin Immunoprecipitation using 9FY



Recruitment of endogenous ERG oncoprotein to regulatory regions of HPGD, c-MYC, KLK3(PSA) and SLC45A3(prostein) genes in VCaP cells are shown by *in vivo* chromatin immunoprecipitation (ChIP) assay using anti-ERG [9FY]. Specificity of ERG recruitment is demonstrated by the knockdown of ERG binding by ERG siRNA. ChIP with IgG is shown as the negative control. Input indicates positive control genomic DNA amplicons.

Images courtesy Dr. Shiv Srivastava, Center for Prostate Disease Research.